This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.
On Wednesday, September 18, Washington’s Prescription Drug Affordability Board (PDAB) finalized its methodology for selecting drugs for affordability reviews. The Board will identify the top 25 drugs from a list of 455 eligible medications based on prioritized rankings that factors in several key data measures: the number of people using the drug, average annual out-of-pocket cost, total annual out-of-pocket cost, and total annual paid amount.
During the meeting, PDAB staff presented various methodologies for selecting prescription drugs for review, with the Board ultimately agreeing to use rankings of key data measures. Following this decision, staff outlined the overall process for conducting affordability reviews but acknowledged that the timeline for completing these reviews remains uncertain. PDAB staff did not indicate when more detailed timeline information would be available.
